Keiko Yanagihara

ORCID: 0000-0003-2708-4550 · 1 paper in corpus

observational 2025

Real-World Outcomes of Subcutaneous PHESGO® in HER2-Positive Breast Cancer: Pathological Response, Sequencing, and Safety

·doi:10.20944/preprints202509.0499.v1

Background: Subcutaneous pertuzumab and trastuzumab with hyaluronidase (PHESGO®) provides a convenient alternative to intravenous dual HER2 blockade, offering markedly shorter administration time. However, real-world evidence in Asian popu…